On Tuesday, SandRidge Energy Inc. (NYSE:SD)’s shares declined -8.57% to $1.92.
SandRidge Energy Inc. (SD) will release its 2015 first quarter shareholder update and financial results after the close of trading on the New York Stock Exchange on Wednesday, May 6, 2015.
SandRidge Energy, Inc., an oil and natural gas company, explores for and produces oil and natural gas properties primarily in the Mid-Continent region of the United States. The company operates through three segments: Exploration and Production, Drilling and Oil Field Services, and Midstream Services.
CAMAC Energy Inc (NYSEMKT:CAK)’s shares gained 449.07% to $4.56.
CAMAC Energy Inc (NYSEMKT:CAK) has been informed by the owner of the Floating Production, Storage, and Offloading vessel (“FPSO”) Armada Perdana, Bumi Armada Berhad, that the renewal of the FPSO’s class certification is now predictable to be accomplished by April 24, 2015.
The Oyo-8 well, located in the Oyo field offshore Nigeria, is ready to commence production into the FPSO upon the vessel’s class certificate renewal.
CAMAC Energy Inc. operates as an independent oil and gas exploration and production company focused on energy resources in Africa. Its asset portfolio comprises of nine licenses covering an area of 43,000 square kilometers, counting production and exploration properties offshore Nigeria; and exploration licenses offshore Ghana, Kenya, and Gambia, in addition to onshore Kenya.
At the end of Tuesday’s trade, EXCO Resources Inc (NYSE:XCO)‘s shares dipped -8.37% to $1.86.
EXCO Resources Inc (XCO) declared that it will be releasing first quarter 2015 results on Tuesday, April 28, 2015, after market close.
EXCO will host a conference call on Wednesday, April 29, 2015, at 9:00 a.m. (Central Time) to talk about the contents of this release and respond to questions
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), ended its Tuesday’s trading session with -7.93% loss, and closed at $0.801.
Oncolytics Biotech, (ONCY) declared that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN®, for the treatment of malignant glioma. The Company applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages. In three previous brain cancer studies counting gliomas, REOLYSIN® has been shown to infect a variety of brain tumors when delivered intravenously.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
